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Common
Exposure to STL
Polyomavirus
During Childhood
Efrem S. Lim, Natalie M. Meinerz, Blake Primi,
David Wang, and Robert L. Garcea
STL polyomavirus (STLPyV) was recently identified in
human specimens. To determine seropositivity for STLPyV,
we developed an ELISA and screened patient samples
from 2 US cities (Denver, Colorado [500]; St. Louis, Missouri [419]). Overall seropositivity was 68%–70%. The agestratified data suggest that STLPyV infection is widespread
and commonly acquired during childhood.

P

olyomaviruses are nonenveloped double-stranded circular DNA viruses that infect a wide range of hosts,
including humans. The capsid of the virus comprises primarily 72 pentamers of the major coat protein, VP1. Human polyomaviruses have been associated with several
diseases (1). BK polyomavirus (BKPyV) has been associated with nephropathy in renal transplant recipients and
JC polyomavirus (JCPyV) with progressive multifocal
leukoencephalopathy in immunocompromised persons
(2,3). Trichodysplasia spinulosa–associated polyomavirus (TSPyV) infection is linked to a rare skin disease in
immunocompromised patients called trichodysplasia spinulosa (4). Furthermore, infection with Merkel cell polyomavirus (MCPyV) in rare instances leads to Merkel cell
carcinomas, an aggressive form of skin cancer (5). Other
polyomaviruses, including WU polyomavirus (WUPyV),
KI polyomavirus (KIPyV), human polyomavirus 6, human polyomavirus 7, human polyomavirus 9, MW polyomavirus (MWPyV), STL polyomavirus (STLPyV), and
human polyomavirus 12, have been identified in specimens from humans, but their role in disease remains to
be defined (1).
Seroepidemiology has played an important role in
establishing the link between human polyomaviruses and
disease and in understanding infection dynamics. The seroprevalences of BKPyV and JCPyV range from 70% to
90% and 40% to 60%, respectively, with an age profile indicating high frequency of early-age infections and lifelong
persistence (6–8). Seropositivity for MCPyV in healthy
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persons ranges from 25% to 64%; all patients with Merkel
cell carcinoma are seropositive (6,9).
STLPyV was recently identified from fecal specimens
from a child in Malawi (10). Viral DNA also was detected
in fecal specimens from the United States and The Gambia, and STLPyV has been found in a surface-sanitized
skin wart surgically removed from the buttocks of a patient
with a primary immunodeficiency called WHIM (warts,
hypogammaglobulinemia, infections, and myelokathexis)
syndrome (11). These observations suggest that STLPyV
might infect humans. We defined the seropositivity rate of
STLPyV in humans using serum from 2 independent US
sites (Denver, Colorado, and St. Louis, Missouri).
The Study
To determine the seropositivity for STLPyV, we developed a capture ELISA using recombinant glutathione
S-transferase–tagged STLPyV VP1 capsomeres (online Technical Appendix, http://wwwnc.cdc.gov/EID/
article/20/9/14-0561-Techapp1.pdf). Electron microscopy
of the STLPyV capsomeres showed 10-nm pentamers
characteristic of polyomaviruses (Figure 1, panel A). We
assessed the specificity of the STLPyV ELISA by preincubating 24 serum samples in the presence and absence
of soluble STLPyV VP1 pentamers before addition to the
immobilized STLPyV glutathione S-transferase–tagged
VP1. The ELISA signal intensity was markedly reduced
when serum was pre-incubated with STLPyV VP1 pentamers (Figure 1, panel B; compare white bars to gray bars).
This result indicates the ELISA seroreactivity could be
self-competed with soluble STLPyV pentamers. STLPyV
shares 55% aa identity in the VP1 region with its next most
closely related polyomavirus, MWPyV (10). Therefore, we
examined whether cross-reactivity existed between STLPyV and MWPyV VP1 capsomeres. Competition assays
with soluble MWPyV VP1 pentamers showed limited interference with the ELISA seroreactivity (Figure 1, panel C;
compare white bars to gray bars). This result indicates that
there was no significant cross-reactivity between STLPyV
and MWPyV VP1 capsomeres. Taken together, these data
demonstrate that the ELISA was specific to STLPyV VP1.
We screened 500 serum specimens collected from
children and adults in Denver for antibodies against STLPyV. The overall seropositivity for STLPyV was 68.0%
(Figure 2, panel A). Children 1–3 years of age had the lowest seropositivity rate (23.8%). In contrast, seroprevalence
of children 4–20 years of age ranged from 61.1% to 70.8%.
Similar seropositivity rates persisted in adults (>21 years of
age), ranging from 68.8% to 74.2%.
We next examined a panel of 419 serum specimens
from St. Louis that had a higher resolution of age-stratification in young infants. The overall seropositivity for
STLPyV was 70.0% (Figure 2, panel B), similar to that
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Figure 2. Age-specific seropositivity for STL polyomavirus (STLPyV)
from serum specimens collected in Denver, Colorado, USA (A), and
St. Louis, Missouri, USA (B). A total of 500 serum specimens from
Denver and 417 from St. Louis were tested for seroreactivity to
STLPyV VP1 proteins. Overall seropositivity in Denver was 68%
and in St. Louis, 70%. Error bars indicate SD.

Figure 1. STL polyomavirus (STLPyV) ELISA. A) Electron
microscopy image shows purified STLPyV VP1 capsomeres. Scale
bar = 100 nm. B) Serum samples were pre-incubated in the absence
(white bars) or presence of soluble STLPyV VP1 pentamers (gray
bars), followed by the STLPyV-capture ELISA. Serum was tested
in triplicate, and average absorbance values are shown. Error bars
indicate SD. Representative data are shown. C) Seroreactivity to
STLPyV in the absence (white bars) or presence of competition with
MW polyomavirus (MWPyV) VP1 pentamers (gray bars) are shown.
Serum was tested in triplicate, and average absorbance values are
shown. Error bars indicate SD. Representative data are shown.

in the specimens from Denver (68.0%). Seropositivity for
STLPyV in infants dropped from 53.3% in the <0.5-year
age group to 37.9% in the 0.5–1-year age group, with the
lowest seropositivity of 22.6% in the 1–2-year group. In
contrast, seropositivity rates for children >2 years of age
were higher, ranging from 60.0% to 85.3%. Finally, seropositivity in adults (>21 years of age) ranged from 91.2% to
95.2%. Thus, these data indicate that exposure to STLPyV
occurs during early childhood and that immune responses
to STLPyV are maintained in adults.
1560

Conclusions
In our analysis of the seroepidemiology of STLPyV
in 2 areas of the United States, we found that prevalence
of the virus was similar (68.0%–70.0%). This prevalence
is slightly higher than the 41.8% for MWPyV, the polyomavirus most closely related to STLPyV (12). However,
the seropositivity of STLPyV is comparable to other human polyomaviruses (>60%), such as BKPyV, KIPyV,
WUPyV, MCPyV, human polyomavirus 6, and TSPyV
(6,8). We found no cross-reactivity with MWPyV VP1, the
most closely-related polyomavirus that shares 55% aa identity in the VP1 region. Thus, the seroepidemiology strongly
supports the notion that STLPyV is a bona fide infectious
agent of humans.
Age stratification of the seropositive specimens suggested an initial waning of immune response followed by
rapid seroconversion during childhood. In the St. Louis
specimens, seropositivity was higher for the <0.5-year and
0.5–1-year age groups (53.3% and 37.9%, respectively)
than for the 1–2-year group (22.6%). This observation was
followed by an increase in STLPyV seropositivity in the
2–3-year group and older age groups (60.0%). Specimens
from Denver were too few to reliably stratify the data to
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the same resolution. Nonetheless, we observed a similar
trend in specimens from Denver where the seropositivity
for the 1–3-year age group (23.8%) was lower than for the
4–6-year group (61.1%). These data indicate that immune
responses to STLPyV decreased in the first 2 years of age,
which suggests waning maternal antibodies. However,
seropositivity was rapidly acquired thereafter, indicating
high exposure of STLPyV in children. Because the specimens were selected from hospital-associated blood draws
of children of unknown health status, seropositivity rates
for healthy children might have varied somewhat from the
results we obtained. Nonetheless, the trends we observed
with STLPyV are similar to profiles that have been reported
for JCPyV, BKPyV, TSPyV, MCPyV, WUPyV, and KIPyV (6,13–15).
STLPyV has not been clearly associated with any
disease. However, the high overall seropositivity rate
suggests widespread infection in the population at large.
None of the pathogenic human polyomaviruses (JCPyV,
BKPyV, MCPyV, TSPyV) have been clearly associated
with acute disease at the time of initial infection. Rather,
immunosuppression is a critical co-factor that is coupled
to the ability of polyomaviruses to persist throughout
life or to integrate into the genome, as in the case of
MCPyV, ultimately leading to disease. Our study demonstrates that a large segment of the general population
has been infected by STLPyV and might harbor persistent
STLPyV infection, assuming the persistence paradigms
of JCPyV and BKPyV hold true for STLPyV. A recent
report identified STLPyV DNA in a skin wart specimen
from an adult with primary immunodeficiency (11). Thus,
it is critical to determine whether human diseases exist
that are caused by STLPyV, especially in immunocompromised persons.
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